ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR) - 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended December 31, 2025 (Fiscal Q1 2026). Arrowhead Pharmaceuticals is a biopharmaceutical company developing RNA interference (RNAi) therapeutics to treat intractable diseases. The company operates as a single segment and reported its first net income in the period, driven by significant collaboration revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased by $261.5 million (10,460%) year-over-year. This was primarily driven by revenue recognition from new collaboration agreements with Sarepta ($229.5 million) and Novartis ($34.2 million).
• Profitability Turnaround: The company shifted from a net loss of $173.1 million to a net income of $30.8 million. Operating income improved by $202.2 million.
• Expense Growth: Research and Development (R&D) expenses increased by $40.2 million (29%) to $177.2 million, driven by higher candidate costs and discovery activities. General and Administrative (G&A) expenses rose by $19.1 million (71%) to $46.0 million, largely due to professional services for commercialization and stock-based compensation.
• Liquidity Position: Cash and cash equivalents decreased by $25.0 million during the quarter due to debt repayments and operating expenses, though total liquid assets (cash + investments) remain robust at approximately $916.6 million.

Guidance, Outlook, and Management Commentary

Strategic Developments:

• Novartis Agreement: Closed a global licensing deal for CNS programs, receiving a $200 million upfront payment (recognized partially in Q1) with up to $2.0 billion in potential milestones.
• Sarepta Milestones: Earned a $200 million milestone payment in November 2025 for the ARO-DM1 program (Myotonic Dystrophy Type 1), received in January 2026.
• Regulatory Approvals: FDA approved REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in November 2025. The FDA also granted Breakthrough Therapy designation for plozasiran in Severe Hypertriglyceridemia (SHTG).
• Pipeline Progress: Initiated Phase 1/2a trials for ARO-MAPT (Alzheimer's) and ARO-DIMER-PA (Cardiovascular). Announced positive interim data for obesity candidates ARO-INHBE and ARO-ALK7.

Subsequent Events (Post-Q1):

• Capital Raise: Completed upsized offerings of convertible senior notes, common stock, and pre-funded warrants in January 2026, raising gross proceeds of $930.0 million.
• China Approval: Received NMPA approval for REDEMPLO in China, triggering a $10.0 million milestone payment.

Risks and Contingencies:

• Litigation: Ongoing patent dispute with Ionis Pharmaceuticals regarding the '333 patent; Ionis's motion to dismiss was granted in December 2025, but the company intends to defend vigorously.
• Debt Covenants: The company maintains a $500 million credit facility with a 15% interest rate (paid in kind) and specific liquidity covenants.

Investor Verification Checklist

• Revenue Recognition Timing: Verify the specific allocation of the $200 million Novartis upfront payment and the $229.5 million Sarepta revenue between current and deferred revenue to understand future earnings visibility.
• Debt Service Obligations: Review the terms of the $500 million credit facility, specifically the "Multiple of Invested Capital" (MOIC) payment requirements and the impact of the 15% PIK interest on the principal balance.
• Commercialization Costs: Assess the sustainability of the 71% increase in G&A expenses as the company transitions to commercial operations for REDEMPLO.
• Pipeline Milestone Probability: Evaluate the likelihood of achieving the $2.0 billion in potential milestones from the Novartis deal and the $250 million remaining from Sarepta.
• Patent Litigation Status: Monitor the outcome of the Ionis Pharmaceuticals patent dispute, as it could impact the commercialization of plozasiran.